Related Experiment Videos
Targeting therapeutic gene expression to human prostate cancers
1YCR Cancer Research Unit, Department of Biology, University of York, Heslington, York, YO10 5YW, UK. njm9@york.ac.uk
Abstract:
Most current therapies against human carcinoma of the prostate are palliative rather than curative. Thus, there is a pressing need for new therapies directed against this common tumor, based on knowledge of the basic biology of the prostate, rather than by extrapolation of treatments from other tumor types. This review presents the various levels of prostate targeting which could be and have been applied, at the attachment, expression and therapeutic gene levels to eliminate prostate carcinoma cells in extraprostatic sites. To achieve optimal and safe targeting, a combination approach will be necessary, as there are few genes whose expression can provide absolute prostate specificity.
Insights
Current prostate cancer treatments are often palliative. New therapies targeting prostate carcinoma require a combination approach based on prostate biology for curative potential.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Current human carcinoma of the prostate therapies are largely palliative, not curative.
- A need exists for novel prostate cancer treatments derived from prostate biology.
- Extrapolation of treatments from other tumor types is insufficient for prostate cancer.
Purpose of the Study:
- To review various prostate targeting strategies for eliminating prostate carcinoma cells.
- To discuss targeting at the attachment, expression, and therapeutic gene levels.
- To highlight the necessity of a combination approach for optimal and safe prostate targeting.
Main Methods:
- Review of existing literature on prostate targeting strategies.
- Analysis of targeting at molecular and genetic levels.
- Evaluation of gene expression for prostate specificity.
Main Results:
- Prostate targeting can be achieved at attachment, expression, and therapeutic gene levels.
- Elimination of extraprostatic prostate carcinoma cells is a key objective.
- Few genes offer absolute prostate specificity, limiting single-target approaches.
Conclusions:
- A combination approach is essential for effective and safe prostate carcinoma targeting.
- Future therapies should leverage a deep understanding of prostate biology.
- Overcoming the challenge of prostate specificity is crucial for curative treatments.